Hostname: page-component-586b7cd67f-dlnhk Total loading time: 0 Render date: 2024-11-23T21:27:36.959Z Has data issue: false hasContentIssue false
  • English
  • Français

Institutional Corruption and the Pharmaceutical Policy

Published online by Cambridge University Press:  01 January 2021

Marc A. Rodwin
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Introduction
Information
Journal of Law, Medicine & Ethics , Volume 41 , Issue 3 , Fall 2013 , pp. 544 - 552
Copyright
Copyright © American Society of Law, Medicine and Ethics 2013

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Lessig, L., Republic, Lost: How Money Corrupts Congress – and a Plan to Stop It (New York: Twelve, 2011); Thompson, D. F., Ethics in Congress: From Individual to Institutional Corruption (Washington, D.C.: The Brookings Institution, 1995); Thompson, D. F., “Two Concepts of Corruption: Making Campaigns Safe for Democracy,” George Washington Law Review 73, no. 5 & 6 (2005): 1036–1069. For other work related to institutional corruption, see the web page of the Lab at the Safra, Edmond J. Center for Ethics, which has links to working papers, blogs, and information about research of Lab Fellows: <http://www.ethics.harvard.edu/lab> (last visited July 29, 2013).Google Scholar
Jorgensen, P. D., “Pharmaceuticals, Political Money, and Public Policy: A Theoretical and Empirical Agenda,” Journal of Law, Medicine & Ethics 41, no. 3 (2013): 553–555.CrossRefGoogle Scholar
Gagnon, M.-A., “Corruption of Pharmaceutical Markets: Addressing the Misalignment of Financial Incentives and Public Health,” Journal of Law, Medicine & Ethics 41, no. 3 (2013): 571–580.CrossRefGoogle Scholar
Rodwin, M. A., “Five Un-Easy Pieces to Pharmaceutical Policy Reform,” Journal of Law, Medicine & Ethics 41, no. 3 (2013): 581–589.CrossRefGoogle Scholar
Light, D. W. Lexchin, J. Darrow, J. J., “Institutional Corruption of Pharmaceuticals and the Myth of Safe and Effective Drugs,” Journal of Law, Medicine & Ethics 41, no. 3 (2013): 590–600.CrossRefGoogle Scholar
Miller, J. E., “From Bad Pharma to Good Pharma: Aligning Market Forces with Good and Trustworthy Practices through Accreditation, Certification, & Rating,” Journal of Law, Medicine & Ethics 41, no. 3 (2013): 601–610.CrossRefGoogle Scholar
Brown, A., “Understanding Pharmaceutical Research Manipulation in the Context of Accounting Manipulation,” Journal of Law, Medicine, & Ethics 41, no. 3 (2013): 611–619.CrossRefGoogle Scholar
Feldman, Y. Gauthier, R. Schuler, T., “Curbing Misconduct in the Pharmaceutical Industry: Insights from Behavioral Ethics and the Behavioral Approach to Law,” Journal of Law, Medicine & Ethics 41, no. 3 (2013): 620–628.CrossRefGoogle Scholar
Gray, G. C., “The Ethics of Pharmaceutical Research Funding: A Social Organization Approach,” Journal of Law, Medicine & Ethics 41, no. 3 (2013): 629–634.CrossRefGoogle Scholar
Sismondo, S., “Key Opinion Leaders and the Corruption of Medical Knowledge: What the Sunshine Act Will and Won't Cast Light On,” Journal of Law, Medicine & Ethics 41, no. 3 (2013): 635–643.CrossRefGoogle Scholar
Cosgrove, L. Wheeler, E., “Drug Firms, Codification of Diagnostic Categories and Bias in Clinical Guidelines,” Journal of Law, Medicine & Ethics 41, no. 3 (2013): 644–653.CrossRefGoogle Scholar
Kassirer, J., On the Take: How Medicine's Complicity with Big Business Can Endanger Your Health (Oxford University Press, 2005).CrossRefGoogle Scholar
Rodwin, M. A., “Rooting Out Institutional Corruption to Manage Inappropriate Off-Label Drug Use,” Journal of Law, Medicine & Ethics 41, no. 3 (2013): 654–664.CrossRefGoogle Scholar
Sah, S. Fugh-Berman, A., “Physicians under the Influence: Social Psychology and Industry Marketing Strategies,” Journal of Law, Medicine & Ethics 41, no. 3 (2013): 665–672.CrossRefGoogle Scholar
Landa, A. S. Elliott, C., “From Community to Commodity: The Ethics of Pharma-Funded Social Networking Sites for Physicians,” Journal of Law, Medicine & Ethics 41, no. 3 (2013): 673–679.CrossRefGoogle Scholar
Rodwin, M. A., “Patient Accountability and Quality of Care: Lessons from Medical Consumerism and the Patients' Rights, Women's Health and Disability Rights Movements,” American Journal of Law and Medicine 20, nos. 1 & 2 (1994): 147–167; Rodwin, M. A., “Exit and Voice in American Health Care,” Michigan Journal of Law Reform 32, no. 4 (1999): 1041–1067.Google Scholar
Rose, S. L., “Patient Advocacy Organizations: Institutional Conflicts of Interest, Trust, and Trustworthiness,” Journal of Law, Medicine & Ethics 41, no. 3 (2013): 680–687.CrossRefGoogle Scholar
Jorgensen, P. D., “Pharmaceuticals, Political Money, and Public Policy: A Theoretical and Empirical Agenda,” Journal of Law, Medicine & Ethics 14, no. 3 (2013): 561–570.CrossRefGoogle Scholar
See Light, Lexchin, Darrow, , supra note 5.Google Scholar
See Rodwin, , supra note 4.Google Scholar
See Sismondo, , supra note 10.Google Scholar
See Brown, , supra note 7.Google Scholar
See Gray, , supra note 9.Google Scholar
See Cosgrove, Wheeler, , supra note 11.Google Scholar
See Sah, Fugh-Berman, , supra note 14.Google Scholar
See Landa, Elliott, , supra note 15.Google Scholar
See Rose, , supra note 17.Google Scholar
See Light, Lexchin, Darrow, , supra note 5; Gagnon, , supra note 3; Rodwin, , supra note 4.Google Scholar
See Rodwin, , supra note 13.Google Scholar
See Brown, , supra note 7.Google Scholar
See Feldman, Gauthier, Schuler, , supra note 8.Google Scholar
See Miller, , supra note 6.Google Scholar
See Sah, Fugh-Berman, , supra note 14.Google Scholar
See Sismondo, , supra note 10.Google Scholar
See Rodwin, , supra note 13.Google Scholar
See Landa, Elliott, , supra note 15.Google Scholar
See Gagnon, , supra note 3.Google Scholar
See Light, Lexchin, Darrow, , supra note 5Google Scholar
Rodwin, M. A., “Conflicts of Interest: The Limitations of Disclosure,” New England Journal of Medicine 321, no. 20 (1989): 1405–1408. See also, Rodwin, M. A., Medicine, Money and Morals: Physicians' Conflicts of Interest (New York: Oxford University Press, 1993): at 213–219; Rodwin, M. A., Conflicts of Interest and the Future of Medicine: The United States, France and Japan (New York: Oxford University Press, 2011): at 214–219.Google Scholar
See Sismondo, , supra note 10.Google Scholar
See Cosgrove, Wheeler, , supra note 11.Google Scholar
See Feldman, Gauthier, Schuler, , supra note 8.Google Scholar
See Rose, , supra note 17.Google Scholar